GeoVax Secures $2.5M Funding to Advance Cancer and Infectious Disease Therapies

GeoVax Labs, Inc., a clinical-stage biotechnology company trading on Nasdaq under GOVX, has announced a significant financial milestone through a registered direct offering with healthcare-focused institutional investors. The company entered into a securities purchase agreement to sell 3,968,256 shares of common stock along with warrants to purchase up to 11,904,768 additional shares at a combined price of $0.63 per unit. This strategic financing move, facilitated by Roth Capital Partners as sole placement agent, is expected to generate approximately $2.5 million in gross proceeds before accounting for placement fees and expenses. The transaction, which closed on September 30, 2025, represents a crucial capital infusion that will support GeoVax's ambitious pipeline of immunotherapies and vaccines targeting both cancer and infectious diseases.

The capital raised through this offering will be strategically deployed to advance GeoVax's diverse portfolio of promising clinical candidates. The company's lead programs include GEO-CM04S1, a next-generation COVID-19 vaccine currently in three separate Phase 2 clinical trials targeting immunocompromised patients, chronic lymphocytic leukemia patients, and healthy individuals seeking more robust protection than current mRNA vaccines provide. In oncology, GeoVax is developing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. Additionally, the company is progressing a vaccine targeting Mpox and smallpox, which has received favorable regulatory guidance from the European Medicines Agency allowing it to advance directly to Phase 3 clinical evaluation. Investors and interested parties can access detailed offering documents through the SEC's website at www.sec.gov, as required by securities regulations.

GeoVax's comprehensive approach to vaccine development and cancer immunotherapy is supported by a strong intellectual property portfolio with worldwide rights. The company's technology platform focuses on creating innovative solutions for challenging medical conditions where current treatments remain inadequate. The successful completion of this financing round demonstrates investor confidence in GeoVax's scientific approach and clinical development strategy. For ongoing updates about clinical trial progress and corporate developments, stakeholders are encouraged to visit the company's official website at www.geovax.com, where they can find the most current information about these potentially transformative medical technologies. This financial backing positions GeoVax to accelerate its research and development efforts across multiple therapeutic areas simultaneously.